NCT04383938View on ClinicalTrials.gov

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
Bladder CancerGastric CancerNon Small Cell Lung CancerNSCLCUrothelial CarcinomaAdvanced Solid Tumor
Interventions
DRUG

APR-246 (eprenetapopt) + Pembrolizumab

APR-246 D1-4 + Pembrolizumab D3

Trial Locations (8)

32224

Mayo Clinic, Jacksonville

37235

Vanderbilt University, Nashville

55902

Mayo Clinic, Rochester

63130

Washington University, St Louis

77030

MD Anderson Cancer Center, Houston

85054

Mayo Clinic, Phoenix

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Center, Boston

Sponsors

Lead Sponsor

Aprea Therapeutics
All Listed Sponsors
lead

Aprea Therapeutics

INDUSTRY

NCT04383938 - Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | Biotech Hunter | Biotech Hunter